Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART101 after Haploidentical HSCT with PT-Cy
NCT05768035Phase 2Recruiting
- Sponsor
- Smart Immune
- Start
- Jun 2023
- Primary completion
- Jul 2025
- Modality
- Hematopoietic Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of SMART101 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by Smart Immune. Primary endpoints: Unexpected Unacceptable Toxicities at 14 days and CD4+ T cell count at 100 days. Started Jun 2023; status: recruiting.
02
Drugs
SMART101
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05768035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768035.